Genetic resistance determinants, in vitro time-kill curve analysis and pharmacodynamic functions for the novel topoisomerase II inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeae

Frontiers in Microbiology

Volumn 6, Issue DEC, 2015, Pages

  Foerster, Sunniva ^a,b   Golparian, Daniel ^b   Jacobsson, Susanne ^b   Hathaway, Lucy J ^a   Low, Nicola ^a   Shafer, William M ^c,d   Althaus, Christian L ^a   Unemo, Magnus ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b Örebro University   (Sweden)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Antimicrobial resistance; DNA topoisomerase II inhibitor; ETX0914; Gonorrhea; Pharmacodynamics; Time kill curve analysis; Treatment

Indexed keywords

AZITHROMYCIN; CEFTRIAXONE; CIPROFLOXACIN; GYRASE INHIBITOR; TETRACYCLINE; ZOLIFLODACIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; COLONY FORMING UNIT; GENE; GENETIC RESISTANCE; GONORRHEA; GYRB GENE; MACA GENE; MTRD GENE; NEISSERIA GONORRHOEAE; NONHUMAN; NORM GENE; PHARMACODYNAMIC PARAMETERS; PHASE 3 CLINICAL TRIAL (TOPIC);

EID: 84954123504     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2015.01377     Document Type: Article

References (41)

1. Alm, R. A., Lahiri, S. D., Kutschke, A., Otterson, L. G., McLaughlin, R. E., Whiteaker, J. D., et al. (2015). Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 59, 1478-1486. doi: 10.1128/AAC.04456-14
2. Asín-Prieto, E., Rodríguez-Gascón, A., and Isla, A. (2015). Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents. J. Infect. Chemother. 21, 319-329. doi: 10.1016/j.jiac.2015.02.001
3. Basarab, G. S., Kern, G. H., McNulty, J., Mueller, J. P., Lawrence, K., Vishwanathan, K., et al. (2015). Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. Sci. Rep. 5:11827. doi: 10.1038/srep11827
4. Breitinger, H.-G. (2012). "Drug synergy-mechanisms and methods of analysis" in Toxicity and Drug Testing, ed. B. Acree (Rijeka: InTech).
5. Cámara, J., Serra, J., Ayats, J., Bastida, T., Carnicer-Pont, D., and Andreu, A., et al. (2012). Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J. Antimicrob. Chemother. 67, 1858-1860. doi: 10.1093/jac/dks162
6. Centers for Disease Control and Prevention [CDC] (2012). Cephalosporin-Resistant Neisseria gonorrhoeae Public Health Response Plan. Atlanta, GA, 1-43. Available at: http://www.cdc.gov/std/treatment/ceph-r-responseplanjuly30-2012.pdf [Accessed July 30, 2015].
7. Chen, C. Y., Nace, G. W., and Irwin, P. L. (2003). A 6 x 6 drop plate method for simultaneous colony counting and MPN enumeration of Campylobacter jejuni, Listeria monocytogenes, and Escherichia coli. J. Microbiol. Methods 55, 475-479. doi: 10.1016/S0167-7012(03)00194-5
8. Chen, M. Y., Stevens, K., Tideman, R., Zaia, A., Tomita, T., Fairley, C. K., et al. (2013). Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia. J. Antimicrob. Chemother. 68, 1445-1447. doi: 10.1093/jac/dkt017
9. Chisholm, S. A., Mouton, J. W., Lewis, D. A., Nichols, T., Ison, C. A., and Livermore, D. M. (2010). Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J. Antimicrob. Chemother. 65, 2141-2148. doi: 10.1093/jac/dkq289
10. Clinical and Laboratory Standards Institute (2014). Performance Standards for Antimicrobial Susceptibility Testing; 24th Informational Supplement. CLSI Document M100-S24. Wayne, PA: CLSI. Available at: http://antimicrobianos.com.ar/ATB/wp-content/uploads/2012/11/M100S22E.pdf
11. Drusano, G. L. (2004). Antimicrobial pharmacodynamics: critical interactions of "bug and drug." Nat. Rev. Microbiol. 2, 289-300. doi: 10.1038/nrmicro862
12. Foerster, S., Unemo, M., Hathaway, L. J., Low, N., and Althaus, C. L. (2015). Time-kill curve analysis and pharmacodynamic functions for in vitro evaluation of antimicrobials against Neisseria gonorrhoeae. bioRxiv doi: 10.1101/028506
13. Golparian, D., Ohlsson, A., Janson, H., Lidbrink, P., Richtner, T., Ekelund, O., et al. (2014a). Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg), Sweden, 2013 and 2014. Euro Surveill. 19:20862. doi: 10.2807/1560-7917.ES2014.19.30.20862
14. Golparian, D., Shafer, W. M., Ohnishi, M., and Unemo, M. (2014b). Importance of multi-drug efflux pumps in the antimicrobial resistance property of clinical multi-drug resistant isolates of Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 58, 3556-3559. doi: 10.1128/AAC.00038-14
15. Gunn, J. S., and Stein, D. C. (1996). Use of a non-selective transformation technique to construct a multiply restriction/modification-deficient mutant of Neisseria gonorrhoeae. Mol. Gen. Genet. 251, 509-517.
16. Huband, M. D., Bradford, P. A., Otterson, L. G., Basarab, G. S., Kutschke, A. C., Giacobbe, R. A., et al. (2015). In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria. Antimicrob. Agents Chemother. 59, 467-474. doi: 10.1128/AAC.04124-14
17. Ison, C. A. (2012). Antimicrobial resistance in sexually transmitted infections in the developed world: implications for rational treatment. Curr. Opin. Infect. Dis. 25, 73-78. doi: 10.1097/QCO.0b013e32834e9a6a
18. Jacobs, M. R. (2001). Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin. Microbiol. Infect. 7, 589-596. doi: 10.1046/j.1198-743x.2001.00295.x
19. Jacobsson, S., Golparian, D., Alm, R. A., Huband, M., Mueller, J., Jensen, J. S., et al. (2014). High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea. Antimicrob. Agents Chemother. 58, 5585-5588. doi: 10.1128/AAC.03090-14
20. Kern, G., Palmer, T., Ehmann, D. E., Shapiro, A. B., Andrews B., Basarab, G. S., et al. (2015). Inhibition of Neisseria gonorrhoeae type II topoisomerases by the novel spiropyrimidinetrione AZD0914. J. Biol. Chem. 290, 20984-20994. doi: 10.1074/jbc.M115.663534
21. Li, R. C., Zhu, M., and Schentag, J. J. (1999). Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials. Clin. Pharmacokinet. 37, 1-16. doi: 10.2165/00003088-199937010-00001
22. Mayer, C., and Janin, Y. L. (2014). Non-quinolone inhibitors of bacterial type IIA topoisomerases: a feat of bioisosterism. Chem. Rev. 114, 2313-2342. doi: 10.1021/cr4003984
23. Meletiadis, J., Pournaras, S., Roilides, E., and Walsh, T. J. (2010). Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrob. Agents Chemother. 54, 602-609. doi: 10.1128/AAC.00999-09
24. Odds, F. C. (2003). Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1. doi: 10.1093/jac/dkg301
25. Ohnishi, M., Golparian, D., Shimuta, K., Saika, T., Hoshina, S., and Iwasaku, K., et al. (2011). Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob. Agents Chemother. 55, 3538-3545. doi: 10.1128/AAC.00325-11
26. Palmer, T., Walkup, G., Basarab, G., Fan, J., Mills, S. D., Shapiro, A., et al. (2014). "AZD0914: a Neisseria gonorrhoeae Topoisomerase II inhibitor with novel mode of inhibition, poster C-1422" in Proceedings of the Abstracts 54th Interscience Conference Antimicrobial Agents Chemotherapy American Society for Microbiology, Washington, DC.
27. Read, P. J., Limnios, E. A., McNulty, A., Whiley, D., and Lahra, M. M. (2013). One confirmed and one suspected case of pharyngeal gonorrhoea treatment failure following 500 mg ceftriaxone in Sydney, Australia. Sex Health 10, 460-462. doi: 10.1071/SH13077
28. Regoes, R. R., Wiuff, C., Zappala, R. M., Garner, K. N., Baquero, F., and Levin, B. R. (2004). Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob. Agents Chemother. 48, 3670-3676. doi: 10.1128/AAC.48.10.3670-3676.2004
29. Ritz, C., and Streibig, J. C. (2005). Bioassay Analysis Using R. J. Stat. Softw. 12. Available at: http://www.jstatsoft.org/v12/i05/paper
30. Unemo, M., Fasth, O., Fredlund, H., Limnios, A., and Tapsall, J. W. (2009). Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J. Antimicrob. Chemother. 63, 1142-1151. doi: 10.1093/jac/dkp098
31. Unemo, M., Golparian, D., and Hestner, A. (2011). Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill. 16:19792.
32. Unemo, M., Golparian, D., Nicholas, R., Ohnishi, M., Gallay, A., and Sednaoui, P. (2012a). High-level cefixime-and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob. Agents Chemother. 56, 1273-1280. doi: 10.1128/AAC.05760-11
33. Unemo, M., Golparian, D., Potocnik, M., and Jeverica, S. (2012b). Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011. Euro Surveill. 17:20200.
34. Unemo, M., and Nicholas, R. A. (2012). Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol. 7, 1401-1422. doi: 10.2217/fmb.12.117
35. Unemo, M., and Shafer, W. M. (2014). Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin. Microbiol. Rev. 27, 587-613. doi: 10.1128/CMR.00010-14
36. Wade, J. J., and Graver, M. A. (2007). A fully defined, clear and protein-free liquid medium permitting dense growth of Neisseria gonorrhoeae from very low inocula. FEMS Microbiol. Lett. 273, 35-37. doi: 10.1111/j.1574-6968.2007.00776.x
37. White, R. L., Burgess, D. S., Manduru, M., and Bosso, J. A. (1996). Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob. Agents Chemother. 40, 1914-1918.
38. World Health Organization and Department of Reproductive Health and Research (2012a). Global Action Plan to Control the Spread and Impact of Antimicrobial Resistance in Neisseria gonorrhoeae. Available at: http://www.who.int/reproductivehealth/publications/rtis/9789241503501/en/[Accessed July 30, 2015].
39. World Health Organization and Department of Reproductive Health and Research (2012b). Global Incidence and Prevalence of Selected Curable Sexually Transmitted Infections-2008. Available at: http://www.who.int/reproductivehealth/publications/rtis/stisestimates/en/[Accessed July 30, 2015].
40. World Health Organization [WHO] (2008). Global Incidence and Prevalence of Selected Curable Sexually Transmitted Infections-2008. Available at: http://www.who.int/reproductivehealth/publications/rtis/2008_STI_estimates.pdf [Accessed July 30, 2015].
41. Zhao, S., Guo, Y., Sheng, Q., and Shyr, Y. (2014). Advanced heat map and clustering analysis using Heatmap3. BioMed. Res. Int. 2014:e986048. doi: 10.1155/2014/986048